Analyst: Novartis's Kesimpta sales exceeded expectations

Genmab may upgrade its financial guidance after the biotech company's partner made more sales than expected of sclerosis drug Kesimpta, a Sydbank analyst predicts.

Photo: Sydbank/PR

Novartis's sales of Genmab-developed drug Kesimpta were better than both the analyst consensus estimate and Sydbank's prediction, which could mean an upgrade to its financial guidance is on the way from Genmab, Senior Analyst Søren Løntoft Hansen states.

Novartis released its Q3 report on Tuesday, revealing that net sales of its scleoris drug totaled USD 109m, which exceeds Sydbank's estimate of USD 90m. The consensus estimate of several analysts collected by Genmab itself was also USD 90m.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs